The Combination of Zidovudine and Interferon AIpha-2B in the Treatment of Adult T-Cell Leukemia/Lymphoma

References

• Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 481–492
   PubMed Web of Science ®Google Scholar
• Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Hematology 1991; 79: 428–437
   PubMed Web of Science ®Google Scholar
• Poiesz B. J., Ruscetti F. W., Gazdar A. F., Bunn P. A., Minna J. D., Gallo R. C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415–7419
   PubMed Web of Science ®Google Scholar
• Gill P. S., Harrington W., Jr, Kaplan M. H., Ribeiro R. C., Bennett J. M., Liebman H. A., Bernstein-Singer M., Espina B. M., Cabral L., Allen S., Kornblau S., Pike M. C., Levine A. M. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332: 1744–1748
   PubMed Web of Science ®Google Scholar
• Bazarbachi A., Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retroviral 1996; 13(Suppl 1)S186–190
   PubMedGoogle Scholar
• Takatsuki K., Yamaguchi K., Kawano F., Hattori T., Nishimura H., Tsuda H., Sanada I., Nakada K., Itai Y. Clinical diversity in adult T-cell leukemia-lymphoma. Cancer Res 1985; 459(Suppl, 46)44s–4645s
   Google Scholar
• Waldmann T. A., White J. D., Carrasquillo J. A., Reynolds J. C., Paik C. H., Gansow O. A., Brechbiel M. W., Jaffe E. S., Fleisher T. A., Goldman C. K., Top L. E., Bamford R., Zaknoen S., Roessler E., Kasten-Sportes C., England R., Litou H., Johnson J. A., Jackson-White T., Manns A., Hanchard B., Junghans R. P., Nelson D. L. Radio-immunotherapy of IL-2Rα-expressing adult T-cell Leukemia with yttrium-90 labeled anti-Tac. Blood 1995; 86: 4063–4075
   PubMed Web of Science ®Google Scholar
• Investigator's Handbook. A manual for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment, National Cancer InstituteRev. Ed. N1H publication no. 93–2770, Government Printing Office, Washington, DC 1993
   Google Scholar
• Korsmeyer S. J., Arnold A., Bakhshi A., Ravetch J. V., Siebenlist U., Hieter P. A., Sharrow S. O., LeBien T. W., Kersey J. H., Poplack D. G., Leder P., Waldmann T. A. Immunoglobulin gene rearrangement and cell surface antigen expression of acute lymphocyte leukemias of T cell and B cell precursor origins. J Clin Invest 1983; 71: 301–313
   PubMed Web of Science ®Google Scholar
• Waldmann T. A. The arrangement of immunoglobulin and T-cell receptor genes in human lymphoproliferative diseases. Adv Immunol 1987; 40: 247–321
   PubMed Web of Science ®Google Scholar
• Tsukasaki K., Ikeda S., Murata K., Maeda T., Atogami S., Sohda H., Momita S., Jubashi T., Yamada Y., Mine M., Kamihiri S., Tomonaga M. Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma. Leukemia Research 1993; 17: 157–166
   PubMed Web of Science ®Google Scholar
• Shimamoto Y., Suga K., Shimojo M., Nishimura J., Nawata H., Yamagughi M. Comparison of CHOP versus VEPA therapy in patients with lymphoma type of adult T-cell leukemia. Leukemia and Lymphoma 1990; 2: 335–340
   PubMed Web of Science ®Google Scholar
• Shimoyama M., Ota K., Kikuchi M., Yunoki K., Konda S., Takatsuki K., Ichimaru M., Tominaga S., Tsugane S., Minato K., Tobinai K., Oyama A., Hisano S., Matsumoto M., Takiguchi T., Yamaguchi K., Kinoshita K., Tajima K., Suemasu K. Lymphoma Study Group (1981–1983) Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin. Oncol 1988; 6: 1088–1097
   PubMed Web of Science ®Google Scholar
• Lymphoma Study Group. Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study (1984–1987). Leukemia Research 1991; 15: 81–90
   PubMed Web of Science ®Google Scholar
• Lofters W., Campbell M., Gibbs W. N., Cheson B. D. 2′-Deoxycoformycin therapy in adult T-cell leukemia/lymphoma. Cancer 1987; 60: 2605–2608
   PubMed Web of Science ®Google Scholar
• Tobinai K., Shimoyama M., Inoue S., Takayasu S., Mikuni C., Kozuru M., Oda S., Nakajima H. Phase I study of YK-176 (2′-deoxycoformycin) in patients with adult T-cell leukemia/lymphoma. Jpn J Clin Oncol 1992; 22: 164–171
   PubMed Web of Science ®Google Scholar
• Dearden C., Matutes E., Catovsky D. Deoxyco-formycin in the treatment of mature T-cell leukemias. British Journal of Cancer 1991; 64: 903–906
   PubMed Web of Science ®Google Scholar
• Honda J., Osabe S., Yosida K., Nakamura E., Tanaka K., Natori H., Oizumi K., Sakamoto A., Imamura Y., Naito K., Egami K. Oral administration of etoposide therapy for refractory malignant lymphoma and adult T-cell lymphoma. Jpn J Cancer Chemother 1991; 18: 653–656
   PubMedGoogle Scholar
• Ohno R., Masaoka T., Shirakawa S., Sakamoto S., Hirano M., Hanada S., Yasunaga K., Yokomaku S., Mitomo Y., Nagai K., Yamada K., Furue H. Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and derivative of bis(2, 6-dioxopiperazine). The MST-16 Study Group. Cancer 1993; 71: 2217–2221
   PubMed Web of Science ®Google Scholar
• Tsuda H., Takatsuki K., Ohno R., Masaoka T., Okada K., Shirakawa S., Ohashi Y., Ota K. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11) CPT-11 Study Group on Hematological Malignancy, Tokyo, Japan. Br J Cancer 1994; 70: 771–774
   PubMed Web of Science ®Google Scholar
• Waldmann T. A., White J. D., Goldman C. K., Top L., Grant A., Bamford R., Roessler E., Horak I. D., Zaknoen S., Kasten-Sportes C., England R., Horak E., Mishra B., Dipre M., Hale P., Fleisher T. A., Junghans R. P., Jaffe E. S., Nelson D. L. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993; 82: 1701–1712
   PubMed Web of Science ®Google Scholar
• Oka T., Ohtsuki Y., Sonobe H., Furihata M., Miyoshi I. Suppressive effects of interferons on the production and release of human T-lymphotropic virus type-I (HTLV-I). Arch Virol 1990; 115: 63–73
   PubMed Web of Science ®Google Scholar
• Isono T., Ogawa K., Seto A. Antiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits. Leuk Res 1990; 14: 841–847
   PubMed Web of Science ®Google Scholar
• Matsushita S., Mitsuya H., Reitz M. S., Broder S. Pharmacological inhibition of in vitro infectivity of human T lymphotrophic virus type I. J Clin Invest 1987; 80: 394–400
   PubMed Web of Science ®Google Scholar
• Koyama Y., Tanaka Y., Oda S., Yamashita U., Eto S. Antiviral and antiproliferative activities of recombinant human interferon alpha 2, beta and gamma on HTLV-I and ATL cells in vitro. Sangyo Ika Daigaku Zasshi 1990; 12: 149–161
   Google Scholar
• Ruprecht R. M., O'Brien L. G., Rossoni L. D., Nusinoff-Lehrmann S. Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature 1986; 323(6087)467–469
   PubMed Web of Science ®Google Scholar
• Melana S. M., Holland J. F., Pogo B. G. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′ deoxythymidine. Clin Cancer Res 1998; 4: 693–696
   PubMed Web of Science ®Google Scholar
• Wagner C. R., Ballato G., Akannin A. O., McIntee E. J., Larson R. S., Chang S., Abdul-Hajj Y. J. Potent growth inhibitory activity of zidovudine on culture human breast cancer cells and rat mammary tumors. Cancer Res 1997; 57: 2341–2345
   PubMed Web of Science ®Google Scholar
• Stark G. R. Interferons: biosynthesis, physiological roles, mechanisms of induction and response. Interferons: mechanisms of action and role in cancer therapy. Monograph, European School of Oncology, D. Crowther. Springer-Verlag, Berlin 1991; 15–23
   Google Scholar
• Pfeffer L. M. Cellular Effects of Interferons. Mechanism of interferon actions, L. M. Pfeffer. CRC Press, Boca Raton, Fla 1987; Vol. II: 1–23
   Google Scholar
• Osman Y., Moriyama Y., Shibata A. Enhanced elimination of Ph+ chromosome cells in vitro by combined hyperthermia and other drugs (AZT, IFN-alpha, TNF, and quercetin): its application to autologous bone marrow transplantation for CML. Exp Hematol 1995; 23: 444–452
   PubMed Web of Science ®Google Scholar
• Estrov Z., Talpaz M., Chou T. C., Kurzrock R., Blake M., Gutterman J. U. Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia. Leukemia 1991; 5: 101–107
   PubMed Web of Science ®Google Scholar
• Nakae H., Asada S. Synergistic antiproliferative effect of interferons and azidothymidine on HL60 cells. Chem Pharm Bull, (Tokyo) 1993; 40: 821–822
   Web of Science ®Google Scholar
• Krown S. E., Gold J. W., Niedzwiecki D., Bundow D., Flomenberg N., Gansbacher B., Brew B. J. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112: 812–21
   PubMed Web of Science ®Google Scholar